san-par time scratch itch upgrad
buy dupix improv profit new
messag upgrad san-par buy neutral price
target pt base view earlier-than-expect profit
antibodi collabor deliv near-term oper leverag strength
dupix expand acceler uptak emerg market growth help
stabil larg establish product overal diabet franchis vaccin
hit opportun new aggress senior leadership pois maxim
sale growth profit
dupix acceler uptak across asthma atop dermat sever
indic provid signific oper leverag antibodi
unbridl enthusiasm dupix activ asthma atop dermat see note
highlight autoimmune/immunolog kol seri part emerg treatment
landscap atop dermat psoriasi estim sever patient
popul across ad asthma alon could exceed patient patient
moder sever diseas fall dupix label could ultim exceed
patient total address market could exceed next decad
addit dupix uniqu well-posit broad reimburs kol indic
reimburs barrier fall appar evid three major
nation formulari includ dupix prefer agent atop dermat
class asthma despit sever competitor expect addit approv
adolesc ad eosinophil esophag chronic rhinosinut nasal polyp
ultim pediatr ad broaden acceler dupix alreadi robust growth
sale forecast exceed well consensu
year
meaning competit ad least year away view jak may
grow market unlik displac dupix multipl class
derm lebrikizumab azn tralokinumab agent reach market
competit vs dupix limit jak inhibitor ad feedback kol
along cautiou take safeti jak class see baricitinib
statist success atop dermat fail safeti rais question
provid runway at-least year dupix see meaning competit
atop dermat market
asthma home deliveri easi reimburs percept greater
efficaci continu drive rapid uptak asthma see note highlight
autoimmune/immunolog kol seri part emerg treatment landscap
moder sever asthma despit competit azn fasenra gsk
nucala expect dupix continu benefit superior market access much
broader label particularli impact among allergist well percept
superior efficaci among pulmonologist view recent news azn fasenra
exclud caremark formulari evid dupix
futur dupix catalyst cement drug leadership role look
forward present detail result atop dermat children
age year age top-lin phase ii result grass allergi allerg
rhiniti top-lin phase ii result dupix peanut
allergi patient year age estim global peak sale
dupix see detail epidemiolog forecast indic
page analyst certif import disclosur
atop dermat asthma antibodi
collabor dupix kevzara praluent
signific invest behind antibodi collabor
profit pois acceler concert guggenheim team suneja
publish first time fulli integr sanofi/regn collabor forecast
forecast collabor contribut profit excess split
sanofi consid antibodi collabor turn profit
forecast remain go forward expect signific leverag within
antibodi collabor vast major commerci overal
 invest behind go forward sanofi invest focu global
expans effort term oper leverag assum sanofi gross margin
increas bp sale oper incom increas
respect lead ep increas optic
sanofi oper margin percentag sale benefit due profit pay-out
robust emerg market help stabil larg diabet establish
product busi despit china headwind plavix aprovel
establish product diabet busi includ plavix aprovel
trend higher primarili driven sale china take closer look forecast
increas estim diabet establish product busi
make chang plavix aprovel estim alreadi anticip impact
china polici expect much competit market oral
healthi profit cash gener sanofi consum busi
set high bar spin sale see new manag goe san-
robust consum healthcar busi annual healthi margin
grow cer henc believ spin consum
busi dilut earn busi oper lower
margin rel valuat ev/ multipl valu consum
healthcar busi
month potenti catalyst includ libtayo lung cancer fitusiran
hemophilia sutimlumab agglutinin diseas isatuximab
combin trial multipl myeloma venglustat fabri gaucher type adpkd
parkinson diseas apart libtayo lung cancer view sanofi pipelin
seri potenti base hit given alreadi low expect like risk/reward
head fitusiran result next month
page analyst certif import disclosur
global sanofi sale busi mix
global sanofi sale busi mix
gpm sale
diseas product cerezym cerdelga fabrazym myozym
compani data guggenheim secur llc estim number may match due round error
page analyst certif import disclosur
global dupix sale indic
global dupix sale region
atop dermat adult
atop dermat pediatr
chronic rhinosinus nasal poli
 sale indic
outsid sale indic
believ atop dermat market worth dupix domin drug key driver
market
atop dermat drive overal global sale dupix follow asthma chronic
rhinosinus nasal polyp
compani data guggenheim secur llc estim number may match due round error
page analyst certif import disclosur
dupix ad market model global sale plenti room
upsid
total patient ad
adult ad patient
moderate/sever diseas
moderate/sever diseas
patient uncontrol w/topic
patient uncontrol w/topic
uncontrol patient requir biolog therapi
patient uncontrol w/topic
dupix penetr adult
adult ad patient treat dupix
dupix adult mm
dupix pediatr mm
total sale ad
dupix adult ou mm
dupix sale pediatr ou mm
total ou sale ad
total sale ad mm adult kid
compani data guggenheim secur llc estim number may match due round error
page analyst certif import disclosur
dupix set high bar atop dermat futur competitor think
biolog jak domin
efficaci result
iga
cs corticosteroid easi eczema area sever index iga investig global assess nr numer rate scale
endpoint efficaci dupix efficaci endpoint vs placebo improv
easi score tool use measur extent area sever atop eczema eczema area sever
reduct baselin eczema area sever index commonli use measur
treatment effect atop dermat ad clinic trial
page analyst certif import disclosur
label moder sever asthma
asthma preval
moder sever
moder sever
patient type diseas
patient type diseas
patient qualifi biolog therapi
patient qualifi biolog therapi
patient treat dupix
annual cost therapi
dupix sale asthma
dupix sale asthma ou
total ww dupix sale asthma
compani data guggenheim secur llc estim number may match due round error
page analyst certif import disclosur
dupix asthma broad label moder sever asthma compar favor
competit think biolog domin sever asthma market
mechan action
mode
sc
block activ
market add-on mainten treatment patient
moderate-to-sever asthma age year older
eosinophil phenotyp oral corticosteroid depend asthma
sc everi
market add-on mainten treatment patient
sever asthma age year older eosinophil
treatment
limit use
bind recruit eosinophil
bone marrow promot
activ longev eosinophil
market add-on mainten treatment patient sever
asthma age year older eosinophil phenotyp
phase ii moder sever asthma
phase moder sever asthma data readout
molecul express cell
fevipipr antagonist
receptor
mediat inflammatori effect
product mast cell
phase iib moder sever eosinophil asthma
tslp mab prevent bind tslp
phase sever asthma data readout
receptor prevent tslp-
activ dendrit cell
mast cell
phase ii sever asthma plan file
page analyst certif import disclosur
market remind us anti-tnf market dupix like humira
hard displac
 sale anti-tnf product evalu pharma
believ dupix humira atop diseas
page analyst certif import disclosur
